Scarica l'app Stockscreener
0.6884
5.58%
-0.0407
Dopo l'orario di chiusura:
.69
0.0016
+0.23%
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR - TradingView
JSPR|Jasper Therapeutics Inc|Price:0.689|Chg%:-0.041 - TradingKey
Jasper Therapeutics Market Sentiment - Benzinga España
Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement - Bitget
Form 4 Jasper Therapeutics Inc For: 22 July By Investing.com - Investing.com Canada
Jasper Therapeutics (JSPR) COO buys non-voting convertible preferred shares - Stock Titan
Jasper Therapeutics (JSPR) EVP outlines option and preferred stakes after Kira deal - Stock Titan
Jasper Therapeutics (JSPR) COO discloses merger-converted option stakes - Stock Titan
Form 4 Jasper Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
Jasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement - Bitget
Jasper Therapeutics (JSPR) director buys preferred stock, granted stock options - Stock Titan
Jasper Therapeutics (JSPR) director details common and preferred stake - Stock Titan
Jasper closes Kira deal, extends cash runway - MSN
Jasper Therapeutics (JSPR) holders outline 3,349,547-share stake after Kira deal - Stock Titan
Jasper Therapeutics stock trades sideways as cash position and clinical pipeline shape outlook - AD HOC NEWS
Jasper Closes Kira Deal, Extends Cash Runway - Benzinga
Jasper gets a lifeline in merger with immune drugmaker Kira - BioPharma Dive
Jasper completes Kira merger, lines up $132 million financing - The Pharma Letter
Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026 - marketscreener.com
Jasper Therapeutics Completes Kira Acquisition and PIPE Financing - TipRanks
Patrick Crutcher appointed to Jasper Therapeutics board; Matthew Ros named COO - TradingView
Jasper Therapeutics (NASDAQ: JSPR) buys Kira, adds $132M PIPE cash - Stock Titan
Jasper Therapeutics acquires Kira, extends cash runway - TipRanks
Jasper Therapeutics acquires Kira Pharmaceuticals for $132m - Investing.com UK
Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy - Bitget
$Jasper Therapeutics (JSPR.US)$ - Moomoo
Jasper Therapeutics acquires Kira Pharmaceuticals for $132m By Investing.com - Investing.com Nigeria
Jasper Therapeutics: Jeet Mahal to Be Pres and CEO of Combined Co - Moomoo
Jasper Therapeutics Merges With Kira Pharmaceuticals - Moomoo
Jasper Therapeutics merges with Kira Pharmaceuticals, raising $132M to advance immunology drug pipeline. - Pluang
Jasper Therapeutics: Combined Co Will Focus on Advancing Consolidated Pipeline of Potential Best-In-Class Innovative Therapies for Immunologically-Driven Disorders >JSPR - Moomoo
Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028 - TradingView
Jasper Therapeutics (NASDAQ: JSPR) closes Kira merger and $132M preferred financing - Stock Titan
Press Release: Jasper Therapeutics Announces Merger With Kira Pharmaceuticals - Moomoo
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals in all-stock deal - Bitget
Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake - Stock Titan
Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Stock Rebounds 6.83% as Biotech Sentiment ImprovesPCR Extreme - dars.gov.et
Jasper Therapeutics stock holds the focus. Company profile stays central. - Ad-hoc-news.de
Enterprise value to EBIT forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Stock Analysis Report | Financials & Insights - Benzinga España
Enterprise value to EBIT forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
Price to book forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
JSPRJasper Therapeutics Inc Options - Finviz
Jasper Therapeutics Inc. (JSPR) Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises, but Stock Drops 5.7%Margin Compression Risk - dars.gov.et
Jasper Therapeutics Q1 2026 Earnings: Sharper-Than-Expected Loss Reduction Fails to Lift StockDividend Growth Analysis - dars.gov.et
Enterprise value to revenue forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):